NO2022038I1 - ropeginterferon alfa-2b - Google Patents

ropeginterferon alfa-2b

Info

Publication number
NO2022038I1
NO2022038I1 NO2022038C NO2022038C NO2022038I1 NO 2022038 I1 NO2022038 I1 NO 2022038I1 NO 2022038 C NO2022038 C NO 2022038C NO 2022038 C NO2022038 C NO 2022038C NO 2022038 I1 NO2022038 I1 NO 2022038I1
Authority
NO
Norway
Prior art keywords
ropeginterferon alfa
ropeginterferon
alfa
Prior art date
Application number
NO2022038C
Other languages
English (en)
Original Assignee
Pharmaessentia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40351178&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2022038(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmaessentia Corp filed Critical Pharmaessentia Corp
Publication of NO2022038I1 publication Critical patent/NO2022038I1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • C07K17/08Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO2022038C 2007-08-16 2022-09-02 ropeginterferon alfa-2b NO2022038I1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95627307P 2007-08-16 2007-08-16

Publications (1)

Publication Number Publication Date
NO2022038I1 true NO2022038I1 (no) 2022-09-02

Family

ID=40351178

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2022038C NO2022038I1 (no) 2007-08-16 2022-09-02 ropeginterferon alfa-2b

Country Status (30)

Country Link
US (1) US8143214B2 (no)
EP (2) EP2205281B1 (no)
JP (1) JP5613050B2 (no)
KR (1) KR101588465B1 (no)
CN (1) CN101367872B (no)
AR (1) AR067964A1 (no)
AU (1) AU2008286742B2 (no)
BR (1) BRPI0814482B8 (no)
CA (1) CA2696478C (no)
CL (1) CL2008002399A1 (no)
CY (2) CY1125751T1 (no)
DK (1) DK2205281T3 (no)
EA (1) EA018111B1 (no)
ES (1) ES2924727T3 (no)
FR (1) FR22C1045I2 (no)
HR (1) HRP20220937T3 (no)
HU (2) HUE059551T2 (no)
LT (1) LT2205281T (no)
MX (1) MX2010001750A (no)
MY (1) MY149148A (no)
NL (1) NL301195I2 (no)
NO (1) NO2022038I1 (no)
NZ (1) NZ583831A (no)
PL (1) PL2205281T3 (no)
PT (1) PT2205281T (no)
SI (1) SI2205281T1 (no)
TW (1) TWI381851B (no)
UA (1) UA103158C2 (no)
WO (1) WO2009023826A1 (no)
ZA (1) ZA201001777B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072850A1 (es) * 2008-07-31 2010-09-22 Pharmaessentia Corp Conjugados peptido-polimero
UA109646C2 (uk) * 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
KR102540109B1 (ko) * 2014-11-06 2023-06-02 파마에센시아 코퍼레이션 Peg화된 인터페론의 투약 요법
CN112433048A (zh) * 2020-11-17 2021-03-02 深圳上泰生物工程有限公司 一种用于化学发光免疫法的试剂盒及其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
JP2003527090A (ja) * 1999-08-27 2003-09-16 マキシゲン・エイピーエス 新規なインターフェロンベータ様分子
HUP0203409A3 (en) * 1999-11-12 2005-06-28 Maxygen Holdings Ltd Redwood C Interferon gamma conjugates
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
BR0214451A (pt) * 2001-11-20 2006-05-30 Pharmacia Corp conjugados do hormÈnio do crescimento humano quimicamente modificado
US20030171285A1 (en) 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
DK3025726T3 (da) 2002-01-18 2019-12-09 Biogen Ma Inc Polyalkylenpolymerforbindelser og anvendelser deraf
US7345150B2 (en) * 2002-03-26 2008-03-18 Medical University Of Toledo Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
KR20050093856A (ko) 2002-09-09 2005-09-23 넥타르 테라퓨틱스 에이엘, 코포레이션 수용성 중합체 알카날
PT2644206T (pt) * 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
EP1694347B1 (en) * 2003-11-24 2013-11-20 BioGeneriX AG Glycopegylated erythropoietin
CN101010105A (zh) 2004-08-31 2007-08-01 法玛西雅厄普约翰有限责任公司 甘油支化的聚乙二醇人生长激素缀合物、其制备方法及其使用方法
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
EP1869079A2 (en) * 2005-03-11 2007-12-26 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
CN101002944B (zh) 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
CN101104078B (zh) 2006-07-11 2011-11-02 北京美倍他药物研究有限公司 多肽及蛋白药物的聚乙二醇偶合物
CN101108895B (zh) 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
CN1966547B (zh) 2006-11-06 2011-11-09 中国药科大学 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
CN1970572A (zh) 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
PL2186830T3 (pl) 2007-09-04 2012-09-28 Biosteed Gene Expression Tech Co Ltd Interferon alfa 2b zmodyfikowany glikolem polietylenowym, jego wytwarzanie i zastosowanie
ES2386575T3 (es) 2007-09-04 2012-08-23 Biosteed Gene Expression Tech. Co., Ltd. Interferón alfa 2a modificado por polietilenglicol, su proceso de síntesis y su aplicación
CN101491682A (zh) 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 聚乙二醇化重组人干扰素ω偶合物及其制备工艺
CN101671390B (zh) 2008-09-10 2012-10-03 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
CN101514229B (zh) 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物

Also Published As

Publication number Publication date
FR22C1045I1 (fr) 2022-10-14
KR20100076945A (ko) 2010-07-06
MX2010001750A (es) 2010-06-01
US8143214B2 (en) 2012-03-27
WO2009023826A1 (en) 2009-02-19
JP5613050B2 (ja) 2014-10-22
CA2696478A1 (en) 2009-02-19
EP2205281A4 (en) 2014-10-08
BRPI0814482B8 (pt) 2021-11-23
CY2022026I1 (el) 2023-06-09
NL301195I1 (no) 2022-08-31
MY149148A (en) 2013-07-15
TWI381851B (zh) 2013-01-11
DK2205281T3 (da) 2022-08-15
TW200916116A (en) 2009-04-16
CN101367872B (zh) 2013-11-20
HRP20220937T3 (hr) 2022-09-30
PL2205281T3 (pl) 2022-12-12
EP2205281B1 (en) 2022-06-29
AU2008286742B2 (en) 2014-05-29
ZA201001777B (en) 2010-12-29
ES2924727T3 (es) 2022-10-10
CY2022026I2 (el) 2023-06-09
EP4129343A1 (en) 2023-02-08
PT2205281T (pt) 2022-08-02
CL2008002399A1 (es) 2009-01-02
EP2205281A1 (en) 2010-07-14
JP2010536788A (ja) 2010-12-02
BRPI0814482A2 (pt) 2015-02-03
SI2205281T1 (sl) 2022-11-30
CN101367872A (zh) 2009-02-18
BRPI0814482B1 (pt) 2021-02-02
UA103158C2 (ru) 2013-09-25
KR101588465B1 (ko) 2016-01-25
NZ583831A (en) 2012-06-29
NL301195I2 (nl) 2023-03-02
HUE059551T2 (hu) 2022-11-28
AU2008286742A1 (en) 2009-02-19
CA2696478C (en) 2018-10-09
US20090053177A1 (en) 2009-02-26
LT2205281T (lt) 2022-09-26
EA201070282A1 (ru) 2010-08-30
EA018111B1 (ru) 2013-05-30
HUS2200039I1 (hu) 2022-09-28
AR067964A1 (es) 2009-10-28
FR22C1045I2 (fr) 2023-12-29
CY1125751T1 (el) 2023-06-09

Similar Documents

Publication Publication Date Title
DE602008006301D1 (de) Koaxialnadelanordnung
BRPI0821573A2 (pt) benzofuropirimidonas
ATE501136T1 (de) Imidazopyridinone
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
DE602008002772D1 (de) Polyvinylpyrrolidonpulverzusammensetzungen
DE112008003636A5 (de) Mehrzuggruppierer
DE502007001207D1 (de) Elektrosaugkopf
BRPI0814519A2 (pt) Organopolissiloxano
BRPI0811451A2 (pt) Exopolissacarídeo
DE602008000923D1 (de) Einzelwaferätzgerät
DE602008000749D1 (de) Buschschneider
BRPI0812840A2 (pt) 2-imidazolinas
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
AT505058A3 (de) Türschliesssystem
DE602008004695D1 (de) Katalysatorträgerwabe
BRPI0812994A2 (pt) Microbiocidas
DE602008001234D1 (de) Bandmaterialzuführvorrichtung
DE602008005950D1 (de) Münzvereinzeler
NO2022038I1 (no) ropeginterferon alfa-2b
DE602008005589D1 (de) Rliganden
DE112008001216A5 (de) Magnetronplasmaanlage
DE502008001694D1 (de) Mitfahrhubwagen
DE602008001674D1 (de) Wimpernwickler
DE112008003094A5 (de) Geomatte
DE602008000292D1 (de) Werkzeughaltepositioniervorrichtung